Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Rare Tumour × atezolizumab × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 57 Carcinoma, Hepatocellular 45 Lung Neoplasms 27 Breast Neoplasms 26 Small Cell Lung Carcinoma 17 Neoplasms 17 Triple Negative Breast Neoplasms 16 Neoplasm Metastasis 16 Carcinoma, Transitional Cell 13 Melanoma 12 Colorectal Neoplasms 12 Urinary Bladder Neoplasms 11 Prostatic Neoplasms 9 Head and Neck Neoplasms 9 Recurrence 8 Ovarian Neoplasms 8 Liver Neoplasms 7 Glioblastoma 7 Mesothelioma, Malignant 6 Endometrial Neoplasms 6 Carcinoma, Renal Cell 6 Sarcoma 5 Rectal Neoplasms 5 Gastrointestinal Neoplasms 5 Carcinoma, Squamous Cell 5 Uterine Cervical Neoplasms 4 Stomach Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 4 Pancreatic Neoplasms 4 Kidney Neoplasms 4

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡